Potential Approach for Fighting Against Corona Virus Disease

  • Mohamed Ali Al-helfawi Medical Tripoli Center-Department of Nephrology.Tripoli-Libya,kortoba 39-5
Keywords: MERS-CoV, (Middle East Rispiratory Syndrome-corona virus), BSAAs, (Broad-Spectrum Antiviral Agents), PCR, (Polymerase Chain Reaction), Q-PCR, (Quantitative Polymerase Reaction), SARS, ( Severe acute respiratory syndrome), SARS-CoV, (Severe acute respiratory syndrome corona virus), siRNA, (short interfering ryboneocliac acid), SMAD, (small.mothers against decapentaplegic family of genes), PRRSV, (Reproductive and Respiratory syndrome), EMT, (Endothelial Mesenchymal Transition)

Abstract

A viral disease (or viral infection, or infectious disease) occurs when pathogenic viruses invade an organism’s body, and infectious virus particles (virions) attach to and enter susceptible cells [1]. There are many types of viral diseases affecting the human body as explained below. But in this approach focus on a noved viral infectious disease belongs to corona viruses group as this dangerous viruses showed a wide spread activity all over the globe. The virus has a characteristic genetic instability means genetic mutations occurs in high rate such a phenomena make the virus replicates with different genetic sequences and spread rapidly therefore, it is not easy to be  controlled neither by vaccines nor by drugs.  This research looking for methods to fight against corona virus through certain mechanisms that have a relationships with transforming growth factor (TGF-beta). Here comes the idea that if we could control TGF-beta, with which the virus interacts, it would be possible to get over the virus either directly or indirectly and at the same giving a chance for the immune system in terms of humeral and cell mediated immunity of the human body to be active against the disease. Taking into account that TGF-beta is a growth factor found everywhere in the body.

References

. Use of serological surveys to generate key insights into the changing global landscape of infectious disease. C Jessica E Metcalf, Jeremy Farrar, Felicity T Cutts, Nicole E Basta, Andrea L Graham, Justin Lessler, Neil M Ferguson, Donald S Burke, Bryan T Grenfell

. "Coronavirus: Common Symptoms, Preventive Measures, & How to Diagnose It". Caringly Yours. 28 January 2020.

. Killerby ME, Biggs HM, Haynes A, Dahl RM, et al. Human coronavirus circulation in the United States 2014 – 2017external icon. Journal of Clinical Virology.V.101; 2018 Apr; 101:52-6.

. (de Haan et al., 2002).

. (Anand et al., 2003; Campanacci et al., 2003; Snijder et al., 2003; Thiel et al., 2003).

. Marra M. A. et al. The Genome sequence of the SARS-associated coronavirus. Science 300, 1399–1404 (2003). [PubMed] [Google Scholar]

. Rota P. A. et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394–1399 (2003). [PubMed] [Google Scholar]

. Nicholls J., Dong X. P., Jiang G. & Peiris M. SARS: clinical virology and pathogenesis. Respirology 8 Suppl, S6–8 (2003). [PubMed] [Google Scholar]

. Wang J. T. & Chang S. C. Severe acute respiratory syndrome. Current opinion in infectious diseases 17, 143–148 (2004). [PubMed] [Google Scholar]

. Wong C. K. et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 136, 95–103 (2004). [PMC free article] [PubMed] [Google Scholar]

. He L. et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol 210, 288–297 (2006). [PubMed] [Google Scholar]

. Gu J. & Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol 170, 1136–1147 (2007). [PMC free article] [PubMed] [Google Scholar]

. Tse G. M. et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 57, 260–265 (2004). [PMC free article] [PubMed] [Google Scholar]

. Velasco-Loyden G., Arribas J., and López-Casillas F. (2004). The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1. J Biol Chem 279: 7721–7733

. Zhang, 2009.

. Kohan D.E. (1991). Endothelin synthesis by renal tubule cells.Am J Physiol 261(2 Pt 2): F221-6.

. Rider C.C. (2006 ). Heparin/heparan sulphate binding in the TGF-beta cytokine superfamily. Biochem

. Chen C.L., Huang S.S., and Huang J.S. (2006). Cellular heparan sulfate negatively modulates transforming growth factor-beta1 (TGF-beta1) responsiveness in epithelial cells. J Biol Chem. Apr 28;281(17):11506-14.

. Presser L. D., McRae S. & Waris G. Activation of TGF-β1 promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF-β1 in hepatic stellate cell activation and invasion. Plos One 8, e56367 (2013). [PMC free article] [PubMed] [Google Scholar] Retracted

. Li S. W. et al. Correlation between TGF-beta1 expression and proteomic profiling induced by severe acute respiratory syndrome coronavirus papain-like protease. Proteomics 12, 3193–205 (2012). [PubMed] [Google Scholar]

. YeWang et al. Silence of TGF-β1 gene expression reduces prrsv replication and potentiates immunity of immune cells of tibetan pig

. Epithelial-derived TGF-β1 acts as a pro-viral factor in the lung during influenza A infection

. Andres J.L., DeFalcis D., et al. (1992). Binding of two growth factor families to separate domains.

. Chun-Lin Chen., Shuan Shian Huang., and Jung San Huang. (2006). Cellular Heparan Sulfate Negatively Modulates Transforming Growth Factor-β1(TGF-β) Responsiveness in Epithelial Cells. The journal of biological chemistry. Vol. 281, NO. 17, pp. 11506-11514.

. Hulpiau P., and van Roy F. (2009). Molecular evolution of the cadherin superfamily. Int. J. Biochem. Cell Biol, 41(2):349-69.

. M.alhelfawi, A.philips.R.steadman. betaglycan as potencial regulator of TGF-beta in the kidney. ASRJETS. 4495-Article Text-13478-1-10-20181213.

. Lee C. H. et al. Altered p38 mitogen-activated protein kinase expression in different leukocytes with increment of immunosuppressive mediators in patients with severe acute respiratory syndrome. J Immunol 172, 7841–7847 (2004). [PubMed] [Google Scholar]

. Beijing Group of National Research Project for SARS. Dynamic changes in blood cytokine levels as clinical indicators in severe acute respiratory syndrome. Chin Med J (Engl) 116, 1283–1287 (2003). [PubMed] [Google Scholar]

. Presser L. D., McRae S. & Waris G. Activation of TGF-β1 promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF-β1 in hepatic stellate cell activation and invasion. Plos One 8, e56367 (2013). [PMC free article] [PubMed] [Google Scholar] Retracted

. Rider C.C. (2006 ). Heparin/heparan sulphate binding in the TGF-beta cytokine superfamily. Biochem

. Li S. W. et al. Correlation between TGF-beta1 expression and proteomic profiling induced by severe acute respiratory syndrome coronavirus papain-like protease. Proteomics 12, 3193–205 (2012). [PubMed] [Google Scholar]

. YeWang et al. Silence of TGF-β1 gene expression reduces prrsv replication and potentiates immunity of immune cells of tibetan pig

. Epithelial-derived TGF-β1 acts as a pro-viral factor in the lung during influenza A infection

. L Denney, W Branchett, L G Gregory, R A Oliver & C M Lloyd

. YeWang et al. Silence of TGF-β1 gene expression reduces prrsv replication and potentiates immunity of immune cells of tibetan pig.

. Tsui, P. 2003. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg. Infect. Dis. 9:1064-1069.CrossRefPubMedWeb of ScienceGoogle Scholar

. Nicholls, J.et al.2003. Lung pathology of fatal severe acute respiratory syndrome. Lancet 361:1773-1778.CrossRefPubMedWeb of ScienceGoogle Scholar

Published
2020-03-22
Section
Articles